TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
NEW YORK, April 24, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of BioAmber Inc. (“BioAmber”) (NYSE:BIOA) (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra/bioamber-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
